AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EyePoint Pharmaceuticals, Inc. Director's Dealing 2021

Jan 13, 2021

32254_dirs_2021-01-13_7259ca92-9b5e-4da8-a885-b49354457e72.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2020-12-31

Reporting Person: Liu Ye (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.001 par value	3010722	Indirect

Footnotes

F1: The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.